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SUMMARY
BACKGROUND
Dupilumab, a monoclonal antibody against interleukin (IL)-4 
receptor alpha that inhibits IL-4/IL-13 signalling is indicated 
in dermatology for the treatment of moderate-to-severe 
atopic dermatitis (AD) in adult and adolescent patients 12 
years and older and severe AD in children 6-11 years, who 
are candidates for systemic therapy. Dupilumab received 
Early Access to Medicines Scheme (EAMS) approval for 
adults in March 2017. 
OBJECTIVES
The purpose of this study was to assess the efficacy outcomes 
of treatment with dupilumab in EAMS. 
METHODS
A retrospective analysis of adult patients enrolled in the 
dupilumab EAMS in the UK. Scores were assessed at 
baseline and follow up, including the Eczema Area and 
Severity Index (EASI), Investigator’s Global Assessment 
Score (IGA) and Dermatology Life Quality Index (DLQI).
RESULTS
Data were available for 57 adult patients treated with 
dupilumab for at least 12 weeks; 73.6% of patients had 
received prior treatment with 3 or 4 immunosuppressants. 
Baseline scores for the EASI and DLQI were 27.93 (standard 
deviation, SD 13.09) and 18.26 (SD 6.18) respectively. AD 
severity scores showed statistically significant improvement 
at week 16+4 weeks (p <0.001 for all). The mean change in 
EASI was 14.13 points with 66.7% and 36.7% achieving a 
50% (EASI-50) and 75% (EASI-75) improvement in EASI, 
respectively at 16+/- 4 weeks.  IGA scores improved by at least 
two categories for 75% patients.  DLQI scores decreased 
by a mean of 9.0 points, with 80% patients demonstrating 
a MCID 4-point improvement. For 85% patients, clinicians 
rated the treatment response as being either ‘better’ (19%) or 
‘much better’ (65%).
CONCLUSIONS
Dupilumab is associated with a significant and clinically 
relevant improvements in AD as measured by patient- and 
physician-reported outcome measures.  Importantly, the 
clinical efficacy, despite the refractory disease of this EAMS 
cohort, is comparable to that previously reported in clinical 
trials.
INTRODUCTION
Systemic therapy is typically considered in atopic dermatitis 
(AD) resistant to topical therapy and where phototherapy is 
ineffective or contraindicated1, 2.  Traditionally used systemic 
agents include azathioprine, methotrexate and ciclosporin. 
Of these, only ciclosporin is licensed in AD and the EMA 
licence limits use up to 12 months. 
Dupilumab, a monoclonal antibody against interleukin (IL)-4 
receptor alpha that inhibits IL-4/IL-13 signalling is indicated 
in dermatology for the treatment of moderate-to-severe 
atopic dermatitis (AD) in adult and adolescent patients 12 
years and older and severe AD in children 6-11 years, who 
are candidates for systemic therapy. 
In the United Kingdom (UK) the Early Access to Medicines 
Scheme (EAMS) aims to give patients with life-threatening 
or seriously debilitating conditions access to medicines that 
do not yet have a marketing authorisation when there is a 
clear unmet medical need. Promising Innovative Medicine 
(PIM) status was granted to dupilumab in December 2015 
and EAMS positive scientific opinion in March 2017. 
Dupilumab was made available to adult patients with 
severe AD who had failed to respond, or who are intolerant 
of, or ineligible for all approved therapies with or without 
corticosteroids. 
The efficacy and safety of dupilumab has been evaluated 
in pivotal randomised, double-blind, placebo-controlled 
studies (SOLO 1, SOLO 2, CAFÉ and CHRONOS) 4, 7.  It is 
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hypothesised that treatment of AD via EAMS would match 
that shown previously in large RCTs. Therefore, the aim 
of this analysis was to assess the efficacy in EAMS a pre-
license access scheme in the UK.
PATIENTS AND METHODS
Patients 
Patient inclusion and exclusion criteria have been listed in 
Table 1. 
Dupilumab was made available to adult patients in the UK 
with severe atopic dermatitis who had failed to respond, 
or who were intolerant of or ineligible for all approved 
therapies. Dupilumab could be used with or without topical 
corticosteroids. 
The study was a retrospective review of the hospital medical 
notes, databases and electronic systems of eligible patients 
(those who had received treatment with dupilumab through 
the EAMS for more than 3 months) with AD recruited to 
EAMS at 8 dermatology sites throughout the UK. All data 
was collected by the clinical teams and overseen by the lead 
dermatologist for EAMS at each site.  
Baseline patient data was available from EAMS entry 
forms held by the sponsor (Sanofi Genzyme). Patients were 
independently selected by their hospital physician in line 
with the EAMS indication; applications were reviewed and 
accepted by the sponsor’s medical lead (RR). Applications 
were received electronically from sites in a pseudo-
anonymised format (initials and date of birth collected), 
once accepted, patients were assigned an EAMS reference 
number and applications were held by the medical team. 
Follow-up data collection and analysis was conducted by an 
independent healthcare research consultancy (York Health 
Economics Consortium, YHEC). Sites were contacted 
directly and provided with paper/electronic clinical report 
forms (CRF). Data were collected in an anonymised format 
by members of the direct care team. Data were only collected 
for patients who had consented at the start of EAMS. The 
collected data were sent in an anonymised format (EAMS 
reference number) to YHEC for data management, analysis 
and report generation.
All data were entered onto data collection forms from 
electronic health records by study site contacts at each site. 
Instruments, clinician rating and data collection
Severity of atopic dermatitis  (AD) was rated by the clinician 
using the Eczema Area and Severity Index (EASI) 5 which 
ranges from 0 to 72, as well as the Investigator’s Global 
Assessment Score (IGA) with scores ranging from 0 to 41. 
EASI scores were categorised as follows: 0 =clear; 0.1 to 1 
= almost clear; 1.1 to 7 = mild disease; 7.1 to 21 = moderate 
disease; 21.1 to 50 = severe disease; >51 = very severe 
disease6.
Patients completed the Dermatology Life Quality Index 
(DLQI)7 with scores ranging from 0 to 30. 
The DLQI scores were categorised as follows: 0 to 1 = 
no effect on patient’s life; 2 to 5 = small effect; 6 to 10 = 
moderate effect; 11 to 20 = very large effect; 21 to 30 = 
extremely large effect8.
Absolute and percentage change were recorded for both 
the EASI and DLQI scores. Also reported was EASI-50 
and EASI-75 (50% and 75% improvement in EASI score, 
respectively).  An EASI reduction of 6.6 points indicates a 
minimally clinically important difference (MCID)9; a 4-point 
reduction is the MCID for the DLQI scores10.
Clinicians also recorded a response to treatment rated on a 
5-point Likert scale: “Much worse”, “Worse”, “About the 
same”, “Somewhat better” and “Much better”.
The timing of follow-up visits varied between patients, 
therefore time since the previous clinic visit was categorised 
as follows: 2 to 4 weeks (14 to 27 days); 4 to 8 weeks (28 to 
55 days); 8 to 12 weeks (56 to 83 days); 12 to 20 weeks (84 
to 139 days; also referred to as 16+4 weeks) and 20 weeks or 
more (>140 days).
Data management and Statistical analysis
A total of 8 EAMS sites based in England and Northern 
Ireland provided data for inclusion in this study. The analysis 
mainly comprised descriptive statistics. Continuous variables 
were summarised using mean and standard deviation, with 
minimum and maximum values reported to provide the 
1  http://www.eczemacouncil.org/research/investigator-global- 
  assessment-scale/
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range. Categorical variables were summarised as frequency 
and proportion.
Inferential statistics were used to assess the statistical 
significance of observed differences for the 16+4 weeks’ 
timeframe. For continuous scale variables a paired samples 
t-test was performed. For ordinal variables a Wilcoxon 
Signed Rank test was performed.
Pearson’s correlations were performed to assess the 
relationships between different measures of severity. 
No imputation was performed for missing data. Missing 
values were excluded from relevant analyses. Precise 
sample sizes are reported for each analysis. Quality control 
was undertaken on the data as follows: each clinical site 
was contacted and the anonymised data for 10% of the total 
patients held at the clinical site were checked against the data 
recorded in the study database.
The analysis was conducted using IBM SPSS Statistics 
software (version 24).
Ethics
This was a retrospective analysis of data. Patient consent 
was obtained prior to enrolment on the EAMS. Anonymised 
data were obtained directly from the patients’ care team. 
This study was approved by the NHS Health Research 
Authority (Reference: 19/HRA/0017, 10th April 2018) and 
all necessary local NHS Trust approvals were obtained.
RESULTS
Patients
The quality control checks revealed no differences between 
data recorded at clinical sites and within the study database. 
Figure 1 depicts the number of patients for whom data were 
available, exclusions and reasons for exclusions. Of the 65 
patients treated with dupilumab via the EAMS scheme, 8 
were excluded due to insufficient data.  The remaining 57 
patients comprised 20 (35.1%) females and 36 males (63.2 
%) with a mean age of 41.2 years (SD: 14.21 years; range: 20 
to 76 years); Gender and age were not available in one and 
two patients, respectively.  
Past immunosuppressant use was reported for 91.2% (52 
patients), the majority of which (73.6%; 42 patients) had 
been prescribed three or four different immunosuppressants. 
The most common immunosuppressants prescribed were 
ciclosporin (86.2%; 50 patients), azathioprine (81.0%; 47 
patients) and methotrexate (70.7%; 41 patients).
Thirty patients (52.6%) were on one immunosuppressant at 
time of enrolment and one patient (1.8%) was on two. In 
these patients, ciclosporin was most common (19.0%; 11 
patients), followed by methotrexate (15.5%; 9 patients).
EASI Scores
Baseline EASI scores were available in 55 of 57 patients and 
ranged from 4.3 (mild disease) to 72.0 (very severe disease)6 
with the most common category being severe disease, and 
Figure 1.  
Diagram demonstrating flow of  
excluded and included patient data.
Table 2. EASI Scores at baseline
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the sample mean values for the full cohort (27.93, SD = 
13.09) corresponding to a rating of severe disease (Table 2).
Follow-up EASI scores were available for 32 patients at 16+/- 
4 weeks (Table 3) with a mean score of 7.62 (SD = 6.26; 
range = 0.0 to 21.6). No patients had ‘very severe’ disease at 
follow-up and only one had ‘severe disease’ based on EASI 
score (Figure 2).
In 30 patients a baseline and 16+/- 4 week follow-up EASI 
score was available. The mean change in EASI score was 
an improvement of 14.13 points (SD= 10.71; range of +9 
to -33). Mean percentage improvement was 55.84% (SD= 
43.01%) between baseline and follow-up at 16+/-4 weeks. 
EASI-50 was observed in 20 patients (66.7%) and EASI-75 
in 11 (36.7%); 22 patients (73.3%) reported a reduction of at 
least 6.6 points, indicative of a MCID.
A paired-samples t-test indicated that the EASI scores at 
the 16+/- 4 week follow-up were significantly lower than at 
baseline (p<0.001).
IGA Scores
Baseline IGA scores were available in 51 of 57 patients. IGA 
scores ranged from 2 (mild) - 4 (severe) with a median score 
of 4 (70.8%, see Table 4).  Both baseline and 16+/- 4 week 
follow-up IGA scores were available for a total of 28 patients 
(Table 5). In 21 (75%) patients the IGA ratings improved by ≥ 
Figure 2. Mean EASI scores at baseline and 16+/-4 weeks
Figure 3. Mean DLQI scores at baseline and 16+/-4 weeks 
Table 3. EASI scores at follow-up
Table 4. IGA scores at baseline
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30 patients for whom both EASI and DLQI change scores 
were available at the 16+/- 4 weeks follow-up, 16 (53.3%) 
achieved an EASI-50 and MCID in DLQI scores.
Table 5. IGA scores at follow-up
Table 6. DLQI scores at baseline
Table 7. DLQI scores at follow-up
2 categories, and in an additional 5 (17.9%) an improvement 
of one category was observed. For one patient there was no 
change and for another and increase in IGA was observed.
A Wilcoxon Signed Rank test indicated that the IGA scores 
at the 16+/- 4 weeks follow-up (median = 1) were significantly 
lower than at baseline (p<0.001).
DLQI Scores
Baseline DLQI scores were available in 54 of 57 patients 
(mean 18.26; SD 6.18, corresponding to ‘very large’ impact) 
(Table 6).  DLQI scores were available at baseline and week 
16+/- 4 in 40 patients. The mean change in DLQI score was 
an improvement of 8.98 points (SD= 7.91; range = 14 to 29 
points). A MCID was observed in 32 patients (80.0%). Of the 
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Table 8.  
Clinician-rated response to treatment at follow-up
Table 9. Correlations between endpoints at follow-up
A paired-samples t-test indicated that the DLQI scores at the 
16+/- 4 week follow-up (mean 8.09) were significantly lower 
than at baseline (mean 17.05; t(39)=7.175, p<0.001). 
Clinician-rated response to treatment at follow-up
The most common clinician-rated treatment response for 
the 26 patients for whom data were available at the 16+/-4 
weeks follow-up was ‘much better’ (65.4%). Two patients 
(7.7%) were graded as worse (105 and 125 days since first 
injection), while a further two were rated as showing no 
change (Table 8).
Relationship between endpoints at follow-up
Table 9 shows the relationship between endpoints at follow-
up. Positive relationships between severity scales were 
significant and considered moderate to strong, particularly 
between the EASI and the IGA (r=0.89, p<0.001).
DISCUSSION
The aim of this study was to investigate the treatment efficacy 
of dupilumab in adult patients with AD treated in EAMS a 
pre-license access scheme in the UK.
The results demonstrated a significant improvement in 
AD severity between baseline and 16 +/-4 week follow-up, 
as measured by EASI and IGA. EASI-50 and EASI-75 
improvements were observed in 67% and 37% respectively 
and importantly a minimally clinically important difference 
of 6.6 points or more was observed in 73%. IGA scores 
improved by at least two categories for 75% patients, 
and by one category for 17.9%.  This corresponded with 
improvements in DLQI scores with a minimally clinically 
important improvement observed in 80%.  Furthermore, a 
clinician-rated treatment response was reported as either 
“better” or “much better” in 19% and 65% of patients, 
respectively.
The efficacy of dupilumab in AD has previously been 
demonstrated in several randomised controlled trials3, 4.  Due 
to the potential of selection bias within clinical trials it is 
important that efficacy of new drugs is also evaluated outside 
the clinical trial setting.  In one recently published real-world 
study of 19 AD patients treated with dupilumab, a median 
SCORAD decrease of 55% and increase in patients with 
IGA of 0/1 from 5% to 61% was observed after 16 weeks11. 
Limitations of that study suggested by the authors included 
the small number of patients and the fact it was based in a 
single-centre. Importantly, our larger multi-centre real-world 
study mirrors these results and the efficacy demonstrated 
within the clinical trial programme despite the fact patients 
treated within EAMS had more refractory disease (75% 
having failed 3-4 prior immunosuppressant drugs, reflecting 
a more severe cohort that those who access in the real-world 
setting either by licence, “candidates for systemic therapy”, 
or by NICE criteria “failure on 1 immnuosupressant”12,13,14). 
Of the pivotal studies, the CAFÉ trial most closely represents 
the EAMS patient population, i.e. failure to respond /
intolerant/inadvisable for ciclosporin. In CAFÉ, an EASI-
50 and DLQI improvement of ≥ 4 was observed in 85% 
and 88% of patients, respectively.  In the present study, we 
observed a 67% EASI-50 and 80% DLQI ≥ 4 improvement.
As with any retrospective study based on secondary use 
of data, interpretation of study endpoints depended on the 
completeness and quality of the source medical records 
and the reliability of the abstraction of data from the 
medical records, meaning potential confounders could not 
be accurately assessed. Full datasets were not available for 
all patients enrolled in EAMS due to missing baseline or 
incomplete follow-up data. Quality control was undertaken 
on a small subset of patients (10%) to minimise disruption at 
the clinical site. Another potential limitation is that no safety 
or adverse events data were recorded as part of this aspect 
of the study. Further data are required from other real-world 
cohorts and registries to further understand the efficacy and 
safety of dupilumab on a wider scale.
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In conclusion, dupilumab is associated with significant 
and clinically-relevant improvements in AD as measured 
by patient- and physician-reported outcome measures. 
Importantly, the clinical efficacy, despite the highly 
immunosuppressant refractory population in this EAMS 
cohort, is comparable to that previously reported in large 
randomised clinical trials.
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